Motus gi announces publication of pure-vu® system clinical data in peer-reviewed journal bmc gastroenterology

Fort lauderdale, fla., june 03, 2021 (globe newswire) -- motus gi holdings, inc., (nasdaq: mots) ("motus gi" or the "company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the publication of data from the reduce (“reliable endoscopic diagnosis utilizing cleansing enhancement”) study in an article titled, “a multicenter, prospective, inpatient feasibility study to evaluate the use of an intra ‑ colonoscopy cleansing device to optimize colon preparation in hospitalized patients: the reduce study” in the peer-reviewed journal bmc gastroenterology. among the important findings that the company continues to emphasize since the data from the reduce study were first announced is the pure-vu system's 97% clinical success rate. the full publication can be found at (click here).
MOTS Ratings Summary
MOTS Quant Ranking